找回密码

Loging

Sinovac to supply Hep A vaccine to Jiangsu province

Published: Tuesday, November 12th, 2013

Sinovac Biotech, a leading China-based vaccine manufacturer, has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply the Company's inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunisation (EPI) in 2014 to the pediatric population in Jiangsu Province.

Share This Article

Sinovac Biotech, a leading China-based vaccine manufacturer, has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply the Company’s inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunisation (EPI) in 2014 to the pediatric population in Jiangsu Province.

The total volume of the tender is up to 1.8 million doses. As one of the two selected suppliers, Sinovac will supply 900,000 doses of Healive to Jiangsu province.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “We are pleased to be selected once again by the Jiangsu CDC as one of the two suppliers of inactivated hepatitis A vaccine pursuant to the tender for the 2014 EPI. We are advancing our strategy to collaborate with the government agencies to provide top-quality vaccines to prevent and control diseases in China and beyond.”

Healive is the first inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. Healive was launched by Sinovac in 2002 in China and is currently available in adult and pediatric dosage forms. In February 2008, the Chinese government included hepatitis A vaccine in its national immunisation program.

V免费订阅电子通讯

* 为必填
多久你想收到电子报? *

公司信息

888 Publishing Ltd


6 Mitre Passage
Greenwich Peninsula
London
SE10 0ER
CO:08048039
t: +44 203 440 7113
f: +44 203 440 7115


loading...
Please Wait...